<DOC>
	<DOCNO>NCT01063140</DOCNO>
	<brief_summary>Rabies immune globulin product lifesaving unvaccinated individual expose rabies virus . Rabies immune globulin make plasma immune donor . Currently practical method obtain plasma immunize normal volunteer Source Plasma donor collect plasma titer adequate . The use rabies vaccine immunization normal Source Plasma donor currently limit level , protective individual , unsuitable production rabies immune globulin . The objective study obtain efficacy safety data regard rabies boostering program demonstrate : 1 . Rabies immune plasma production substantially increase give booster dose previously immunize donor whose titer 10.0 IU/mL . 2 . It safe normal Source Plasma donor receive booster dos rabies vaccine regular basis . This study utilize two rabies vaccine approve FDA , Imovax® ( Sanofi-Pasteur ) RabAvert® ( Novartis ) .</brief_summary>
	<brief_title>Rabies Immune Plasma Booster Study</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Meet requirement Source Plasma donor Completed initial series rabies antibody injection serious adverse event least 90 day prior enrollment Compliance program requirement Signed informed consent Failure meet requirement Source Plasma donor Noncompliance program Experience serious adverse reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Rabies Immune Globulin</keyword>
	<keyword>Source Plasma Donors</keyword>
	<keyword>Booster Immunization</keyword>
</DOC>